United States:
PTAB Denies Institution Of Kyle Bass IPRs - But Not For Improper Purpose
25 August 2015
Foley & Lardner
To print this article, all you need is to be registered or login on Mondaq.com.
The USPTO Patent Trial and Appeal Board (PTAB) issued it first
institution decisions on IPR petitions filed by Kyle Bass and his
Coalition for Affordable Drugs, denying institution of his
challenges to two Orange-book listed patents for Ampyra. Many were
watching to see if the PTAB would render a decision based on the
"improper purpose" of the challenges, but the PTAB
decisions are based on more substantive grounds. For a first look
at the PTAB decisions, see
this article on Foley's PharmaPatentsblog.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.